LP-471756 is a potent GPR139 antagonist (inhibitor) with IC50 of 640 nM. LP-471756 inhibits LP-360924-stimulated cAMP production.

Physicochemical Properties

Molecular Formula	C19H23NO2S
Molecular Weight	329.456423997879
Exact Mass	329.14
Elemental Analysis	C, 69.27; H, 7.04; N, 4.25; O, 9.71; S, 9.73
CAS #	413605-11-5
PubChem CID	789353
Appearance	White to off-white solid powder
LogP	5.2
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	4
Heavy Atom Count	23
Complexity	456
Defined Atom Stereocenter Count	0
InChi Key	STLMNZVBCJVQOZ-UHFFFAOYSA-N
InChi Code	InChI=1S/C19H23NO2S/c1-15-7-5-6-10-19(15)20-23(21,22)18-13-11-17(12-14-18)16-8-3-2-4-9-16/h5-7,10-14,16,20H,2-4,8-9H2,1H3
Chemical Name	4-cyclohexyl-N-(2-methylphenyl)benzenesulfonamide
Synonyms	LP 471756; LP-471756; LP471756
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	GPR139 ( IC50 = 640 nM )
ln Vitro	LP-471756 (0-1000 µM) nacre suppresses cAMP production in GPR139 cells in response to LP-360924 stimulation with an IC50 value of 0.64 µM[2].
References	[1]. Pharmacology and function of the orphan GPR139 G protein-coupled receptor. Basic Clin Pharmacol Toxicol. 2020 Jun;126 Suppl 6(Suppl 6):35-46. [2]. Identification of surrogate agonists and antagonists for orphan G-protein-coupled receptor GPR139. J Biomol Screen. 2009 Aug;14(7):789-97.

Solubility Data

Solubility (In Vitro)

DMSO: ~250 mg/mL (~758.8 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 2.08 mg/mL (6.31 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (6.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.0353 mL	15.1763 mL	30.3527 mL
	5 mM	0.6071 mL	3.0353 mL	6.0705 mL
	10 mM	0.3035 mL	1.5176 mL	3.0353 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.